Cargando…

ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitro

Single-nucleotide polymorphisms (SNPs) in the gene coding for the efflux-transport protein ABCB1 (P-glycoprotein) are commonly inherited as haplotypes. ABCB1 SNPs and haplotypes have been suggested to influence the pharmacokinetics and therapeutic outcome of the tyrosine kinase inhibitor (TKI) imati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Skoglund, Karin, Moreno, Samuel Boiso, Baytar, Maria, Jönsson, Jan-Ingvar, Gréen, Henrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3760445/ https://www.ncbi.nlm.nih.gov/pubmed/24019750 http://dx.doi.org/10.2147/PGPM.S45522

Ejemplares similares

Modulating the function of ABCB1: in vitro and in vivo characterization of sitravatinib, a tyrosine kinase inhibitor
por: Yang, Yuqi, et al.
Publicado: (2020)

ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines
por: Eadie, Laura N., et al.
Publicado: (2016)

Bruton’s Tyrosine Kinase (BTK) Inhibitor RN486 Overcomes ABCB1-Mediated Multidrug Resistance in Cancer Cells
por: Dong, Xing-Duo, et al.
Publicado: (2020)

Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors
por: Lemos, C, et al.
Publicado: (2008)

The Resistance of Cancer Cells to Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, is Mediated by the ABCB1 Transporter
por: Fu, Han, et al.
Publicado: (2022)

Association of Extrarenal Adverse Effects of Posttransplant Immunosuppression With Sex and ABCB1 Haplotypes
por: Venuto, Rocco C., et al.
Publicado: (2015)

Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells
por: Wu, Chung-Pu, et al.
Publicado: (2023)

Tyrosine Kinase Inhibitors as Reversal Agents for ABC Transporter Mediated Drug Resistance
por: Anreddy, Nagaraju, et al.
Publicado: (2014)

Isobavachalcone as an Active Membrane Perturbing Agent and Inhibitor of ABCB1 Multidrug Transporter
por: Palko-Łabuz, Anna, et al.
Publicado: (2021)

In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib
por: Redaelli, Sara, et al.
Publicado: (2015)

The Phosphodiesterase-5 Inhibitor Vardenafil Is a Potent Inhibitor of ABCB1/P-Glycoprotein Transporter
por: Ding, Pei-Rong, et al.
Publicado: (2011)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

Nanomedicine of tyrosine kinase inhibitors
por: Smidova, Veronika, et al.
Publicado: (2021)

Association between ABCB1 polymorphisms and haplotypes and Alzheimer’s disease: a meta-analysis
por: Zhong, Xin, et al.
Publicado: (2016)

The ABCB1 transporter gene and antidepressant response
por: Peters, Eric J, et al.
Publicado: (2009)

Molecular insights into the human ABCB6 transporter
por: Song, Guangyuan, et al.
Publicado: (2021)

Identification and Empiric Evaluation of New Inhibitors of the Multidrug Transporter P-Glycoprotein (ABCB1)
por: Cheema, Yasmeen, et al.
Publicado: (2023)

A Unique In Vitro Assay to Investigate ABCB4 Transport Function
por: Temesszentandrási-Ambrus, Csilla, et al.
Publicado: (2023)

ABCB1 genotypes and haplotypes in patients with dementia and age-matched non-demented control patients
por: Frankfort, Suzanne V, et al.
Publicado: (2006)

Latest progress in tyrosine kinase inhibitors
por: Pospelova, Tatiana V., et al.
Publicado: (2014)

Tyrosine kinase inhibitors in sarcoma treatment
por: Kyriazoglou, Anastasios, et al.
Publicado: (2022)

In Vitro and In Vivo Inhibition of MATE1 by Tyrosine Kinase Inhibitors
por: Uddin, Muhammad Erfan, et al.
Publicado: (2021)

Transport Mechanisms and Their Pathology-Induced Regulation Govern Tyrosine Kinase Inhibitor Delivery in Rheumatoid Arthritis
por: Schmidt-Lauber, Christian, et al.
Publicado: (2012)

Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance
por: Wang, Yi-Jun, et al.
Publicado: (2014)

Differential Inhibition of Equilibrative Nucleoside Transporter 1 (ENT1) Activity by Tyrosine Kinase Inhibitors
por: Jouan, Elodie, et al.
Publicado: (2021)

The Role of Organic Cation Transporters in the Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of Tyrosine Kinase Inhibitors
por: Xiu, Fangrui, et al.
Publicado: (2023)

Interaction Potential of the Multitargeted Receptor Tyrosine Kinase Inhibitor Dovitinib with Drug Transporters and Drug Metabolising Enzymes Assessed in Vitro
por: Weiss, Johanna, et al.
Publicado: (2014)

Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
por: Labots, Mariette, et al.
Publicado: (2016)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Influence of the Bile Acid Transporter Genes ABCB4, ABCB8, and ABCB11 and the Farnesoid X Receptor on the Response to Ursodeoxycholic Acid in Patients with Nonalcoholic Steatohepatitis
por: Kreimeyer, Henriette, et al.
Publicado: (2023)

ABCB1 transporter and Toll-like receptor 4 in trabecular meshwork cells
por: Grybauskas, Algis, et al.
Publicado: (2015)

Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis
por: Gomez-Puerta, Jose A., et al.
Publicado: (2013)

Reversing multidrug resistance by tyrosine kinase inhibitors
por: He, Miao, et al.
Publicado: (2012)

Fasting plus tyrosine kinase inhibitors in cancer
por: Caffa, Irene, et al.
Publicado: (2015)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)

Targeting tumour microenvironment by tyrosine kinase inhibitor
por: Tan, Hor-Yue, et al.
Publicado: (2018)

Tyrosine Kinase Inhibitors in Pulmonary Vascular Disease
por: Ryan, John J.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_a072ghdhjeos2gu6jhvj473fct